Lulu Lyu
吕璐璐
Lulu Lyu is a biotech executive who co-founded Huyuan Biotechnology (合源生物) in June 2018 and serves as its CEO . She came from a large multinational pharmaceutical firm, where she had helped bring drugs like Gleevec (imatinib) to the Chinese market, and launched Huyuan with the goal of developing China's own CAR-T therapy . The company's lead product, an injection for acute lymphoblastic leukemia, had treated over 100 Chinese patients in clinical studies as of mid-2023 . The venture was backed by Dalton Venture (道彤投资), which profiled her as part of its portfolio .
AI-generated — may contain errors, please verify.
Coverage
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Rooted in Reality, Driven by Innovation, Moving Forward Without Pause | Dalton Venture's 2024 Annual Partners Meeting Successfully Concludes
Pressing forward into the real, advancing toward the new — the resolve to push ahead undimmed.
New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
A Visit to a Dalton Venture Family Company | Heyuan Bio's Lulu Lyu: China's Homegrown CAR-T Therapy Is About to Become Reality, Bringing New Hope for Relapsed or Refractory Acute Lymphoblastic Leukemia Patients
"After nearly five years, He Yuan Bio's first core product, inaticabtagene autoleucel injection, has treated more than 100 Chinese patients in clinical studies for acute lymphoblastic leukemia — representing the largest accumulated dataset to date on CD19 CAR-T clinical safety and efficacy in a Chinese patient population."
